Literature DB >> 16775333

LMP1 strain variants: biological and molecular properties.

Bernardo A Mainou1, Nancy Raab-Traub.   

Abstract

The ubiquitous herpesvirus Epstein-Barr virus (EBV) is linked to the development of several malignancies, including nasopharyngeal carcinoma. Latent membrane protein 1 (LMP1) is considered the EBV oncogene as it is necessary for EBV-induced transformation of B lymphocytes and is able to transform Rat-1 fibroblasts. LMP1 can activate a wide array of signaling pathways, including phosphatidylinositol 3-kinase (PI3K)-Akt and NF-kappaB. Six sequence variants of LMP1, termed Alaskan, China 1, China 2, Med+, Med-, and NC, have been identified, and individuals can be infected with multiple variants. The frequencies of detection of these variants differ for various EBV-associated malignancies from different geographic regions. In this study, the biological and signaling properties of the LMP1 variants have been characterized. All of the LMP1 variants transformed Rat-1 fibroblasts, induced increased motility of HFK cells, and induced increased homotypic adhesion of BJAB cells. While all the variants activated the PI3K-Akt signaling pathway to similar extents, the Alaskan, China 1, and Med+ variants had limited binding to the E3 ubiquitin ligase component homologue of Slimb and had slightly enhanced NF-kappaB signaling. These findings indicate that the signature amino acid changes of the LMP1 variants do not hinder or enhance their in vitro transforming potentials or affect their signaling properties.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16775333      PMCID: PMC1488979          DOI: 10.1128/JVI.00135-06

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  61 in total

1.  Phenotypic alterations induced by the Hong Kong-prevalent Epstein-Barr virus-encoded LMP1 variant (2117-LMP1) in nasopharyngeal epithelial cells.

Authors:  Angela Kwok Fung Lo; Dolly P Huang; Kwok Wai Lo; Yiu Loon Chui; Hoi Ming Li; Jesse Chung Sean Pang; Sai-Wah Tsao
Journal:  Int J Cancer       Date:  2004-05-10       Impact factor: 7.396

2.  Expression of Epstein-Barr virus transformation-associated genes in tissues of patients with EBV lymphoproliferative disease.

Authors:  L Young; C Alfieri; K Hennessy; H Evans; C O'Hara; K C Anderson; J Ritz; R S Shapiro; A Rickinson; E Kieff
Journal:  N Engl J Med       Date:  1989-10-19       Impact factor: 91.245

3.  Epstein-Barr virus latent membrane protein 1 is essential for B-lymphocyte growth transformation.

Authors:  K M Kaye; K M Izumi; E Kieff
Journal:  Proc Natl Acad Sci U S A       Date:  1993-10-01       Impact factor: 11.205

4.  Sequence variation in the Epstein-Barr virus latent membrane protein 1.

Authors:  W E Miller; R H Edwards; D M Walling; N Raab-Traub
Journal:  J Gen Virol       Date:  1994-10       Impact factor: 3.891

5.  Epstein-Barr virus latent membrane protein (LMP1) and nuclear proteins 2 and 3C are effectors of phenotypic changes in B lymphocytes: EBNA-2 and LMP1 cooperatively induce CD23.

Authors:  F Wang; C Gregory; C Sample; M Rowe; D Liebowitz; R Murray; A Rickinson; E Kieff
Journal:  J Virol       Date:  1990-05       Impact factor: 5.103

6.  Activation of nuclear factor-kappaB p50 homodimer/Bcl-3 complexes in nasopharyngeal carcinoma.

Authors:  Natalie J Thornburg; Rajadurai Pathmanathan; Nancy Raab-Traub
Journal:  Cancer Res       Date:  2003-12-01       Impact factor: 12.701

7.  Epstein-Barr virus latent membrane protein 1 (LMP1) upregulates Id1 expression in nasopharyngeal epithelial cells.

Authors:  H M Li; Z H Zhuang; Q Wang; J C S Pang; X H Wang; H L Wong; H C Feng; D Y Jin; M T Ling; Y C Wong; A G Eliopoulos; L S Young; D P Huang; S W Tsao
Journal:  Oncogene       Date:  2004-05-27       Impact factor: 9.867

8.  Biology of Epstein-Barr virus during infectious mononucleosis.

Authors:  Diane L Sitki-Green; Rachel Hood Edwards; Mary M Covington; Nancy Raab-Traub
Journal:  J Infect Dis       Date:  2004-01-13       Impact factor: 5.226

9.  Potential selection of LMP1 variants in nasopharyngeal carcinoma.

Authors:  Rachel H Edwards; Diane Sitki-Green; Dominic T Moore; Nancy Raab-Traub
Journal:  J Virol       Date:  2004-01       Impact factor: 5.103

10.  Latent infection membrane protein transmembrane FWLY is critical for intermolecular interaction, raft localization, and signaling.

Authors:  Teruhito Yasui; Micah Luftig; Vishal Soni; Elliott Kieff
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-26       Impact factor: 11.205

View more
  45 in total

1.  The nucleotide polymorphisms within the Epstein-Barr virus C and Q promoters from nasopharyngeal carcinoma affect transcriptional activity in vitro.

Authors:  Feng-Wei Wang; Xian-Rui Wu; Wen-Ju Liu; Ying-Jie Liang; Yu-Fan Huang; Yi-Ji Liao; Chun-Kui Shao; Yong-Sheng Zong; Shi-Juan Mai; Dan Xie
Journal:  Eur Arch Otorhinolaryngol       Date:  2011-12-07       Impact factor: 2.503

2.  An update on Epstein-Barr virus and nasopharyngeal carcinogenesis.

Authors:  Bayardo Perez-Ordoñez
Journal:  Head Neck Pathol       Date:  2007-12-01

3.  Unique signaling properties of CTAR1 in LMP1-mediated transformation.

Authors:  Bernardo A Mainou; David N Everly; Nancy Raab-Traub
Journal:  J Virol       Date:  2007-07-11       Impact factor: 5.103

4.  Comparative analysis of oncogenic properties and nuclear factor-kappaB activity of latent membrane protein 1 natural variants from Hodgkin's lymphoma's Reed-Sternberg cells and normal B-lymphocytes.

Authors:  Nathalie Faumont; Aurélie Chanut; Alan Benard; Nadine Cogne; Georges Delsol; Jean Feuillard; Fabienne Meggetto
Journal:  Haematologica       Date:  2009-02-11       Impact factor: 9.941

Review 5.  Roles of the PI3K/Akt pathway in Epstein-Barr virus-induced cancers and therapeutic implications.

Authors:  Jiezhong Chen
Journal:  World J Virol       Date:  2012-12-12

Review 6.  Chemoprevention of head and neck squamous cell carcinoma through inhibition of NF-κB signaling.

Authors:  Robert Vander Broek; Grace E Snow; Zhong Chen; Carter Van Waes
Journal:  Oral Oncol       Date:  2013-10-28       Impact factor: 5.337

7.  Modified Anoikis Assay That Functionally Segregates Epstein-Barr Virus LMP1 Strains into Two Groups.

Authors:  Laura R Wasil; Kathy H Y Shair
Journal:  J Virol       Date:  2018-08-29       Impact factor: 5.103

8.  Effect of Epstein-Barr virus sequence variation on performance of the Roche real-time LightCycler PCR assay.

Authors:  Tao Feng; Fei Ye; Josephine Wu; Shiquan Jiang; Jennifer Coolbaugh; Benjamin Shneider; Betsy Herold; Sukru Emre; David Y Zhang
Journal:  J Clin Microbiol       Date:  2008-05-14       Impact factor: 5.948

9.  Epstein-Barr virus genetic variation in Vietnamese patients with nasopharyngeal carcinoma: full-length analysis of LMP1.

Authors:  Do Nguyen-Van; Ingemar Ernberg; Ingemar Enrberg; Phi Phan-Thi Phi; Chinh Tran-Thi; LiFu Hu
Journal:  Virus Genes       Date:  2008-07-29       Impact factor: 2.332

10.  Tumor-derived variants of Epstein-Barr virus latent membrane protein 1 induce sustained Erk activation and c-Fos.

Authors:  Maria Vaysberg; Olivia Hatton; Stacie L Lambert; Andrew L Snow; Bonnie Wong; Sheri M Krams; Olivia M Martinez
Journal:  J Biol Chem       Date:  2008-11-05       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.